Compare NWPX & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWPX | ALT |
|---|---|---|
| Founded | 1966 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 610.5M | 415.3M |
| IPO Year | 1995 | N/A |
| Metric | NWPX | ALT |
|---|---|---|
| Price | $64.22 | $3.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $62.50 | $16.33 |
| AVG Volume (30 Days) | 63.8K | ★ 4.7M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.50 | N/A |
| EPS | ★ 3.66 | N/A |
| Revenue | ★ $519,991,000.00 | $20,000.00 |
| Revenue This Year | $8.18 | N/A |
| Revenue Next Year | $1.02 | N/A |
| P/E Ratio | $17.50 | ★ N/A |
| Revenue Growth | ★ 7.64 | N/A |
| 52 Week Low | $36.97 | $2.90 |
| 52 Week High | $65.84 | $8.05 |
| Indicator | NWPX | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 69.99 | 34.70 |
| Support Level | $63.85 | $3.83 |
| Resistance Level | $65.31 | $5.37 |
| Average True Range (ATR) | 1.51 | 0.39 |
| MACD | 0.15 | -0.20 |
| Stochastic Oscillator | 78.37 | 1.43 |
NWPX Infrastructure Inc is a manufacturer of water-related infrastructure products. The Company is the manufacturer of engineered water transmission systems in North America and produces steel casing pipe, bar-wrapped concrete cylinder pipe, and pipeline system joints and fittings through its Engineered Steel Pressure Pipe segment. The Company provides solution-based products for a wide range of markets, including high-quality reinforced precast concrete products, lined precast sanitary sewer system components, water distribution and management equipment, including pump lift stations, wastewater pretreatment, and stormwater quality products through its Precast Infrastructure and Engineered Systems segment.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.